Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer

Breast Cancer Research and Treatment

Volumn 102, Issue 3, 2007, Pages 301-312

  Gordon, N H ^a,b   Silverman, P ^b   Lasheen, W ^b   Meinert, J ^b   Siminoff, L A ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; Comorbidity; Long term follow up; Recurrence; Second primary; Survival; Tamoxifen

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BACTERIAL INFECTION; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSE; PRIORITY JOURNAL; RACE; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; METHOTREXATE; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 33947497245     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9338-1     Document Type: Article

References (30)

1. Hubay CA, Pearson OH, Marshall JS, Rhodes RS, Debanne SM, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL (1980) Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer. Euro J Cancer Suppl 1:189-195
2. Hubay CA, Gordon NH, Pearson OH, Marshal JS, McGuire WL (1985) Eight-year follow-up of adjuvant therapy for stage II breast cancer. World J Surg 9:738-749
3. Fisher B (1977) Biological and clinical considerations regarding the use of surgery and chemotherapy in treatment of primary breast cancer. Cancer 40:574-587
4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294(8):405-410
5. EORTC (1972) Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer. Euro J Cancer 8:387-389
6. Cole MP, Jones CT, Todd ID (1971) A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25(2):270-275
7. Engelsman E, Korsten CB, Persian JP, Clapton FJ (1973) Human breast cancer and estrogen receptor. Archive chirurgical Neerlandicum 25(4):393-397
8. Esber HJ, Menninger FF Jr, Taylor DJ, Bogden AE (1972) Nonspecific stimulation of tumor-associated immunity by methanol-soluble fraction of Mycobacterium butyricum. Cancer Res 32:795-803
9. McGuire W, DeLaGarza M (1973) Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab 37:986-989
10. 2001 Physician ICD 9 CM, International classification of diseases, vols 1 & 2, 9th Revision, Clinical Modification, 6th edn. MEDICODE, Medicode, 5225 Wiley Post Way, Suite 500,Salt Lake City, UT 84116, 2001
11. Charlson ME, Pompei P, Ales KL, MacKenzie CD (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and Validation. J Chron Dis 40:373-383
12. D'Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32:382-387
13. Gordon NH, Crowe JP, Brumberg DJ, Berger NA (1992) Socio-economic factors and race in breast cancer recurrence and survival. Am J Epidemiol 135:609-618
14. Gordon NH (1995) The association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142:796-803
15. Gordon NH (2003) Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev 22:55-56
16. Collett D (1994) Modelling survival data in medical research. Chapmann and Hall, London, UK
17. So Y (1999) Lifetest procedure. SAS/STAT Version 8, SAS Institute Inc., Carey NC
18. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-220
19. Breslow NE (1974) Covariance analysis of censored survival data. Biometrics 30:89-100
20. So Y (1999) PHREG procedure. SAS/STAT Version 8, SAS Institute Inc., Carey NC
21. Warwick J, Tabar L, Bedrich V, Duffy SW (2004) Time-dependent effects on survival in breast carcinoma: Results of 20 years of follow-up from the Swedish two-county study. Cancer 100:1331-1336
22. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Igle JN, Pritchard KI, Schneider DF, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK for SWOG, ECOG, NCCTG, and NCIC-CTG. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG 8814). Proceedings of ASCO, v 21, 2002
23. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12:2078-2085
24. Taylor SG 4th, Knuiman MW, Sleeper LA, Olson JE, Tormey DC, Gilchrist KW, Falkson G, Rosenthal SN, Carbone P, Cummings FJ (1989) Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. Journal of clinical oncology 7:879-889
25. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of cheomtherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
26. Newman LA, Griffith KA, Jtoi I, Simon MS, Crowe JP, Colditz GA (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol: Official J Am Soc Clin Oncol 24(9):1342-1349
27. Lagerlund M, Bellocco R, Karlsson P, Tejler G, Lambe M (2005) Socio-economic factors and breast caner survival - a population-based cohort study (Sweden). Cancer Causes Control 16(4):419-430
28. Bigby J, Holmes MD (2005) Disparities across the breast cancer continuum. Cancer Causes Control 16:35-44
29. Gordon NH (1990) Application of the theory of finite mixtures for the estimation of 'cure' rates of treated cancer patients. Stat Med 9:397-407
30. Gordon NH (1995) Cure mixture models in breast cancer survival studies. In Jewell NP, Kimber AC, Ting Lee M-L, Whitmore GA (eds), Lifetime data: models in reliability and survival analysis. Boston, pp 107-112